US-based oncology company TriSalus Life Sciences has entered a strategic partnership with Geo-Med, a certified Service-Disabled Veteran-Owned Small Business (SDVOSB).
The collaboration aims to expand access to the TriNav Infusion System (TriNav) through US Department of Veterans Affairs (VA) medical centres across the US.
Geo-Med has two decades of experience as a key supplier to the VA and the US Department of Defence (DOD) medical facilities.
Building on its expertise in providing high-quality medical products, along with insight into VA procurement, Geo-Med would ensure that TriNav reaches the veterans.
Geo-Med CEO Mike Locke said: “We are proud to collaborate with TriSalus to bring this innovative delivery technology to veterans. Liver cancer is a particularly aggressive disease, and by expanding access to TriNav, we’re providing veterans with the latest advancements in treatment.”
TriSalus CEO and president Mary Szela said: “Fittingly, on the day honouring our veterans, we announce this pivotal collaboration designed to expand access for US veterans to our proprietary Pressure-Enabled Drug Delivery (PEDD) approach.
“PEDD is enabled by TriNav, a promising technology with the potential to improve liver cancer outcomes. We are thrilled to partner with Geo-Med to increase access to TriNav for veterans battling liver cancer.
“This collaboration is closely aligned with our mission to enhance patient outcomes, particularly for those who have served our country.”
TriSalus Life Sciences is a medical technology business providing disruptive drug delivery technology to improve therapeutics delivery to liver and pancreatic tumours.
Its two FDA-approved devices leverage its unique Pressure-Enabled Drug Delivery (PEDD) approach to deliver a range of therapeutics.
The two devices include the TriNav Infusion System for hepatic arterial infusion of liver tumours and the Pancreatic Retrograde Venous Infusion System for pancreatic tumours.
PEDD is designed to modulate the pressure and flow to deliver more therapeutic to the tumour and reduce undesired delivery to normal tissue, to improve patient outcomes.
The approach is said to address the limitations of arterial infusion for the pancreas.
